Mindfulness experience for young people at risk of psychosis
Part of Mental health clinical trials.
This study explores how young people who are at high risk for psychosis or have had a first episode experience mindfulness. It uses interviews to understand their personal experience, which could help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 15 and 30 years old.
- You are at ultra-high risk for psychosis or have had a first episode of psychosis, based on a specific assessment (CAARMS scale).
- This condition must also affect your daily life, such as work, school, or social activities.
- You have not had a previous diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.
- You have not taken antipsychotic medication for more than 12 months.
- You must be able to speak French well enough to take part in an interview that will be audio recorded.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether mindfulness training can help young people at high risk for psychosis avoid developing a full psychotic disorder. If you are between 18 and 30 and have early signs of psychosis, this program might be a way to get support and learn skills to stay well.
This trial tests a telehealth (video/phone) version of cognitive behavioral therapy to help young people who are at risk for developing psychosis. It may help by teaching skills to reduce symptoms and improve coping, with support from a key family or close person.
This study tests a program to help young people who are at risk for psychosis and have had suicidal thoughts or behaviors. The program also involves a caregiver, like a family member, to provide support.
This study is testing a new French version of a questionnaire (SPI-CY) that helps doctors better understand early signs of psychosis in teenagers. If you are 12 to 17 and already being checked for these signs, you may be able to help improve the tool.
This study tests a support program for young people in Tunisia who show early signs of possible psychosis. It aims to help them before more serious symptoms develop.
This trial tests if cannabidiol (a non-psychoactive cannabis component) can prevent psychosis in people ages 12-35 at high risk. It compares CBD to a placebo to see if it reduces symptoms and delays or prevents a first psychotic episode.
Hear when a new Clinical High Risk for Psychosis (CHR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.